Andrew White, MD

Articles by Andrew White, MD

Role of Biomarkers in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 26th 2023

Experts outline biomarkers to measure asthma, highlighting eosinophil count and fractional exhaled nitric oxide levels.

Trends in Biologic Treatment of Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 26th 2023

Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.

Switching Biologic Treatment in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 19th 2023

Experts comment on switching from 1 biologic treatment to another, as well as combining biologics with steroids or other treatments in asthma.

Optimizing Biologic Treatment Selection in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 19th 2023

Andrew White, MD, discusses choosing the right biologic for patients with severe asthma, considering factors such as asthma comorbidities as well as patient preference.

Use of Dupilumab in Treatment of Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 12th 2023

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the efficacy and safety of dupilumab for the treatment of asthma, as well as which patients are good candidates for dupilumab.

Dual Inhibition of Interleukins by Dupilumab in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 12th 2023

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, provides an overview of the difference between single and dual inhibition of interleukins, focusing on dupilumab as a dual inhibitor for asthma treatment.

Use of Biologic Treatment in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 5th 2023

Experts discuss the use of biologic agents to manage asthma and describe the mechanisms of action of different biologics.

Overuse of Oral Corticosteroids in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

July 5th 2023

Medical expert highlights the risk of overuse of oral corticosteroids in the management of asthma and reviews alternative treatment options.

Use of Guidelines to Classify Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 28th 2023

Andrew White, MD, reviews the definition of difficult-to-treat or severe asthma as outlined in the GINA (Global Initiative for Asthma) guidelines.

Treatment Selection for Severe Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 28th 2023

Experts discuss the process of choosing a treatment plan for patients with severe allergic or eosinophilic asthma.

Treatment Landscape of Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 21st 2023

Andrew White, MD, provides an overview of the asthma treatment landscape, focusing on inhaled and oral corticosteroids, as well as biologic and nonbiologic agents.

Predicting Exacerbation of Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 21st 2023

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the tools available to predict the exacerbation of asthma, highlighting spirometry and biomarkers as effective tools

Signs of Severe Asthma and the Underlying Pathophysiology

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 14th 2023

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the symptoms of coughing, wheezing, and shortness of breath as a product of an overactive immune system and as a sign of asthma.

Role of Type 2 Inflammation in Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 7th 2023

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, describes the mechanism of type 2 inflammation and comments on it being a prominent issue among patients with asthma.

Overview of Asthma

ByRaffi Tachdjian, MD, MPH,Dareen Siri, MD, FAAAAI, FACAAI,Nicole Chase, MD, FAAP, FACAAI, FAAAAI,Andrew White, MD

June 7th 2023

Andrew White, MD, provides an overview of the difference of asthma endotypes and phenotypes as a way to define and diagnose asthma.

Final Thoughts on Management of Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 22nd 2022

Drs Anju Peters, Naveen Bhandarkar, Andrew White, and Dareen Siri share takeaway thoughts on the management of nasal polyposis.

Unmet Needs in Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 22nd 2022

Drs Anju Peters, Naveen Bhandarkar, Andrew White, and Dareen Siri review unmet needs and shared decision making in the treatment of nasal polyposis.

Emerging Treatment Options for Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 22nd 2022

A multidisciplinary panel reviews emerging treatment options for nasal polyposis, including EDS-FLU, Tezepelumab, and Rimegepant.

Use of Clinical Trials for Patients with Nasal Polyps

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 15th 2022

Drs Anju Peters and Naveen Bhandarkar, comment on the challenges of using biologic therapies to treat patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).

Challenges in the Use of Biologics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 15th 2022

Drs Anju Peters and Naveen Bhandarkar, comment on the challenges of using biologic therapies to treat patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).

Biologics for Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 8th 2022

A panel of experts highlights the role of biologics in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Changing Treatment for Patients with Nasal Polyps

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 8th 2022

Drs Anju Peters, Naveen Bhandarkar, Andrew White, and Dareen Siri discuss their approach to changing treatment for patients with chronic rhinosinusitis either with or without nasal polyps.

Role of EDS-FLU in Clinical Practice in Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 1st 2022

A multidisciplinary panel discusses the role of EDU-FLU in their individual practices.

Use of Steroids After Surgery in Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

December 1st 2022

Drs Anju Peters and Naveen Bhandarkar comment on the use of steroids after surgery for nasal polyposis.

EDS-PLU Studies for Treatment of Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

November 24th 2022

Expert allergists provide an overview of the phase 3 studies with EDS-FLU for treatment of nasal polyposis.

Use of Steroid Eluting Stents in Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

November 24th 2022

Naveen Bhandarkar, MD, shares his thoughts on the role of steroid eluting stents in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Bioabsorbable Sinus Implants for Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

November 17th 2022

Naveen Bhandarkar, MD, discusses the use of sinus implants for the treatment of nasal polyposis.

Large Volume Corticosteroid Delivery System for Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

November 17th 2022

Andrew White, MD, reviews large volume corticosteroid delivery devices for patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Small Volume Corticosteroid Delivery Systems for Nasal Polyposis

ByAnju Peters, MD,Naveen Bhandarkar, MD,Andrew White, MD,Dareen Siri, MD, FAAAAI, FACAAI

November 10th 2022

Dareen Siri, MD, FAAAAI, FACAAI, highlights small volume corticosteroid delivery systems for patients with nasal polyps and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).